164513-39-7

Basic information

• Product Name: 5-BROMO-2-METHOXY-4-METHYLPYRIDINE
• Synonyms: 2-METHOXY-5-BROMO-4-PICOLINE;5-BROMO-2-METHOXY-4-METHYLPYRIDINE;5-BROMO-2-METHOXY-4-PICOLINE;5-BROMO-2-METHOXY-4-METHYLPYRIDINE, 96+%;2-METHOXY-5-BROMO-4-METHYLPYRIDINE;5-BroMo-2-Methoxy-4-Methylpyridine;5-Bromo-2-methoxy-4-methylpyridine 5-Bromo-2-methoxy-4-picoline
• CAS NO: 164513-39-7
• Molecular Formula: C₇H₈BrNO
• Molecular Weight: 202.05
• Product Categories: Pyridine;Heterocyclic Compounds;Heterocycles;Boronic Acid;C7 and C8Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridines;Pyridine Series;Isoquinolines ,Quinolines ,Quinazolines ,Quinaldines
• Mol File: 164513-39-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 33-37 °C(lit.)
• Boiling Point: 229.632 °C at 760 mmHg
• Flash Point: 225 °F
• Appearance: beige moist crystals
• Density: 1.452 g/cm³
• Vapor Pressure: 0.104mmHg at 25°C
• Refractive Index: 1.538
• Storage Temp.: 0-10°C
• PKA: 1.70±0.18(Predicted)
• CAS DataBase Reference: 5-BROMO-2-METHOXY-4-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-METHOXY-4-METHYLPYRIDINE(164513-39-7)
• EPA Substance Registry System: 5-BROMO-2-METHOXY-4-METHYLPYRIDINE(164513-39-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 164513-39-7(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-methoxy-4-methylpyridine is a chemical compound with the molecular formula C7H8BrNO. It is a pyridine derivative with a bromine atom, a methoxy group, and a methyl group attached to the pyridine ring. 5-BROMO-2-METHOXY-4-METHYLPYRIDINE is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is also used as an intermediate in organic synthesis for the production of various functionalized pyridine derivatives. 5-Bromo-2-methoxy-4-methylpyridine has applications in the development of new drugs and crop protection products, making it an important compound in the field of medicinal and agricultural chemistry.

InChI:InChI=1/C7H8BrNO/c1-5-3-7(10-2)9-4-6(5)8/h3-4H,1-2H3

Upstream product

• 100848-70-2 2-methoxy-4-methyl-pyridine 
• 67-56-1 methanol 
• 864830-16-0 5-bromo-2-fluoro-4-methyl-pyridine 
• 778611-64-6 5-bromo-2-chloro-4-methylpyridine 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 
• 164513-38-6 2-hydroxy-5-bromo-4-methylpyridine 
• 74-88-4 methyl iodide 

Downstream Products

• 503184-35-8 (6-methoxy-4-methylpyridin-3-yl)boronic acid 
• 123506-66-1 6-methoxy-4-methylnicotinaldehyde 
• 1093951-66-6 2-methoxy-4-methyl-5-(4 ,4 ,5 ,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 943635-10-7 6-methoxy-4-methylnicotinic acid hydrochloride 
• 1214388-41-6 C₁₂H₁₁NO 
• 1590402-73-5 C₂₁H₂₁NO₃ 
• 1214389-77-1 C₁₃H₁₃NO 
• 943719-62-8 6-methoxy-4-methylnicotinic acid 

Relevant articles and documents

IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.

PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1, 5-a]-1,3,5-triazines: Potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists

This report describes the syntheses and structure-activity relationships of 8-(substituted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF1) receptor antagonists. These CRF1 receptor antagonists may be potential anxiolytic or antidepressant drugs. This research resulted in the discovery of compound 13-15, which is a potent, selective CRF1 antagonist (hCRF1 IC50 = 6.1 ± 0.6 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors. This compound also has a good pharmacokinetic profile in dogs. Analogue 13-15 is orally effective in two rat models of anxiety: the defensive withdrawal (situational anxiety) model and the elevated plus maze test. Analogue 13-15 has been advanced to clinical trials.